LumiThera’s LIGHTSITE IIIB Extension Trial Topline Results Show Extended Vision Improvement in Dry AMD Subjects

by Business Wire • 2025/05/08 • 0 Comments

SEATTLE--(BUSINESS WIRE)-- #DryAMD--LumiThera’s LIGHTSITE IIIB Extension Trial Topline Results Show Extended Vision Improvement in Dry AMD Subjects Treated with Valeda

← Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)

Warby Parker Announces First Quarter 2025 Results →

Post navigation